{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:10:20Z","timestamp":1792512620309,"version":"4.5.0"},"reference-count":111,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hypertension represents one of the primary and most common risk factors leading to the development of heart failure (HF) across the entire spectrum of left ventricular ejection fraction. A large body of evidence has demonstrated that adequate blood pressure (BP) control can reduce cardiovascular events, including the development of HF. Although the pathophysiological and epidemiological role of hypertension in the development of HF is well and largely known, some critical issues still deserve to be clarified, including BP targets, particularly in HF patients. Indeed, the management of hypertension in HF relies on the extrapolation of findings from high-risk hypertensive patients in the general population and not from specifically designed studies in HF populations. In patients with hypertension and HF with reduced ejection fraction (HFrEF), it is recommended to combine drugs with documented outcome benefits and BP-lowering effects. In patients with HF with preserved EF (HFpEF), a therapeutic strategy with all major antihypertensive drug classes is recommended. Besides commonly used antihypertensive drugs, different evidence suggests that other drugs recommended in HF for the beneficial effect on cardiovascular outcomes exert advantageous blood pressure-lowering actions. In this regard, type 2 sodium glucose transporter inhibitors (SGLT2i) have been shown to induce BP-lowering actions that favorably affect cardiac afterload, ventricular arterial coupling, cardiac efficiency, and cardiac reverse remodeling. More recently, it has been demonstrated that finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces new-onset HF and improves other HF outcomes in patients with chronic kidney disease and type 2 diabetes, irrespective of a history of HF. Other proposed agents, such as endothelin receptor antagonists, have provided contrasting results in the management of hypertension and HF. A novel, promising strategy could be represented by small interfering RNA, whose actions are under investigation in ongoing clinical trials.<\/jats:p>","DOI":"10.3390\/ijms25126661","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T03:42:06Z","timestamp":1718682126000},"page":"6661","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Hypertension and Heart Failure: From Pathophysiology to Treatment"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4845-117X","authenticated-orcid":false,"given":"Giovanna","family":"Gallo","sequence":"first","affiliation":[{"name":"Clinical and Molecular Medicine Department, Faculty of Medicine and Psychology, Sant\u2019Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-1959","authenticated-orcid":false,"given":"Carmine","family":"Savoia","sequence":"additional","affiliation":[{"name":"Clinical and Molecular Medicine Department, Faculty of Medicine and Psychology, Sant\u2019Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and etiology of heart failure","volume":"13","author":"Ziaeian","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_2","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1789\u20131858."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: A comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/HYPERTENSIONAHA.120.16483","article-title":"Worldwide Trends in Prevalence, Mortality, and Disability-Adjusted Life Years for Hypertensive Heart Disease from 1990 to 2017","volume":"77","author":"Dai","year":"2021","journal-title":"Hypertension"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","article-title":"The progression from hypertension to congestive heart failure","volume":"275","author":"Levy","year":"1996","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The Transition from Hypertension to Heart Failure: Contemporary Update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Lifetime risk for developing congestive heart failure: The Framingham Heart Study","volume":"106","author":"Larson","year":"2002","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jchf.2016.08.001","article-title":"Hypertension, Obesity, Diabetes, and Heart Failure-Free Survival: The Cardiovascular Disease Lifetime Risk Pooling Project","volume":"4","author":"Ahmad","year":"2016","journal-title":"JACC Heart Fail."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lasica, R., Djukanovic, L., Vukmirovic, J., Zdravkovic, M., Ristic, A., Asanin, M., and Simic, D. (2024). Clinical Review of Hypertensive Acute Heart Failure. Medicina, 60.","DOI":"10.3390\/medicina60010133"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/jch.14553","article-title":"Targets and management of hypertension in heart failure: Focusing on the stages of heart failure","volume":"24","author":"Miao","year":"2022","journal-title":"J. Clin. Hypertens."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J. Hypertens."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jacc.2022.07.005","article-title":"Harmonization of the American College of Cardiology\/American Heart Association and European Society of Cardiology\/European Society of Hypertension Blood Pressure\/Hypertension Guidelines: Comparisons, Reflections, and Recommendations","volume":"80","author":"Whelton","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1205475","DOI":"10.3389\/fcvm.2023.1205475","article-title":"Hypertensive heart disease: Risk factors, complications, and mechanisms","volume":"10","author":"Masenga","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCULATIONAHA.113.001878","article-title":"Pathological ventricular remodeling: Mechanisms: Part 1 of 2","volume":"128","author":"Burchfield","year":"2013","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Triposkiadis, F., Sarafidis, P., Briasoulis, A., Magouliotis, D.E., Athanasiou, T., Skoularigis, J., and Xanthopoulos, A. (2023). Hypertensive Heart Failure. J. Clin. Med., 12.","DOI":"10.3390\/jcm12155090"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jash.2011.08.006","article-title":"Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)-possible therapeutic perspectives","volume":"5","author":"Cacciapuoti","year":"2011","journal-title":"J. Am. Soc. Hypertens."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9767","DOI":"10.1007\/s11033-022-07468-0","article-title":"Interplay between PI3K\/AKT pathway and heart disorders","volume":"49","author":"Hussen","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.47162\/RJME.62.3.08","article-title":"Hypertension induces compensatory left ventricular hypertrophy by a mechanism involving gap junction lateralization and overexpression of CD36, PKC, and MMP-2","volume":"62","author":"Dumitrescu","year":"2021","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s10020-023-00701-x","article-title":"Polymorphic variants at NDUFC2, encoding a mitochondrial complex I subunit, associate with cardiac hypertrophy in human hypertension","volume":"29","author":"Gallo","year":"2023","journal-title":"Mol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Gallo, G., Rubattu, S., and Volpe, M. (2024). Mitochondrial Dysfunction in Heart Failure: From Pathophysiological Mechanisms to Therapeutic Opportunities. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052667"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/01.RES.81.5.857","article-title":"Role of tissue renin in the regulation of aldosterone biosynthesis in the adrenal cortex of nephrectomized rats","volume":"81","author":"Volpe","year":"1997","journal-title":"Circ. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41569-020-00480-6","article-title":"Cellular and molecular pathobiology of heart failure with preserved ejection fraction","volume":"18","author":"Mishra","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/00004872-200204000-00027","article-title":"Functional cross-talk between angiotensin II and epidermal growth factor receptors in NIH3T3 fibroblasts","volume":"20","author":"Porcellini","year":"2002","journal-title":"J. Hypertens."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"48617","DOI":"10.1074\/jbc.M206532200","article-title":"Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy","volume":"277","author":"Doevendans","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1161\/HYPERTENSIONAHA.120.15527","article-title":"Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling during Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension","volume":"76","author":"Savoia","year":"2020","journal-title":"Hypertension"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/HJH.0b013e32835f17e5","article-title":"Right ventricular hypertrophy in systemic hypertension: An updated review of clinical studies","volume":"31","author":"Cuspidi","year":"2013","journal-title":"J. Hypertens."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/HJH.0b013e328339f943","article-title":"In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: The Losartan Intervention for Endpoint reduction study","volume":"28","author":"Wachtell","year":"2010","journal-title":"J. Hypertens."},{"key":"ref_30","first-page":"5","article-title":"The relative impact of circumferential and longitudinal shortening on left ventricular ejection fraction and stroke volume","volume":"17","author":"Maciver","year":"2012","journal-title":"Exp. Clin. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/heartjnl-2021-319605","article-title":"Heart failure with preserved ejection fraction: Recent concepts in diagnosis, mechanisms, and management","volume":"108","author":"Gevaert","year":"2022","journal-title":"Heart"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3389\/fphys.2019.00638","article-title":"Heart Failure with Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology","volume":"10","author":"Gevaert","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1161\/01.CIR.0000048123.22359.A0","article-title":"Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: Implications for systolic and diastolic reserve limitations","volume":"107","author":"Kawaguchi","year":"2003","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cardfail.2021.07.012","article-title":"Hemodynamics for the Heart Failure Clinician: A State-of-the-Art Review","volume":"28","author":"Hsu","year":"2022","journal-title":"J. Card. Fail."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11906-020-1017-9","article-title":"Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy","volume":"22","author":"Nwabuo","year":"2020","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/heartjnl-2015-308403","article-title":"Evidence of microvascular dysfunction in heart failure with preserved ejection fraction","volume":"102","author":"Lee","year":"2016","journal-title":"Heart"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"35028","DOI":"10.18632\/oncotarget.26164","article-title":"Chronic heart failure is characterized by altered mitochondrial function and structure in circulating leucocytes","volume":"9","author":"Coluccia","year":"2018","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00018-023-04777-w","article-title":"Atrial natriuretic peptide stimulates autophagy\/mitophagy and improves mitochondrial function in chronic heart failure","volume":"80","author":"Raffa","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1093\/eurheartj\/ehu353","article-title":"Biomechanical factors in atherosclerosis: Mechanisms and clinical implications","volume":"35","author":"Kwak","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"798958","DOI":"10.3389\/fmed.2021.798958","article-title":"Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications","volume":"8","author":"Gallo","year":"2022","journal-title":"Front. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Gallo, G., and Savoia, C. (2024). New Insights into Endothelial Dysfunction in Cardiometabolic Diseases: Potential Mechanisms and Clinical Implications. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052973"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/archinternmed.2010.427","article-title":"Antihypertensive treatment and development of heart failure in hypertension: A Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk","volume":"171","author":"Sciarretta","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(09)61340-4","article-title":"Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): An open-label randomized trial","volume":"374","author":"Verdecchia","year":"2009","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"ACCORD Study Group, Cushman, W.C., Evans, G.W., Byington, R.P., Goff, D.C., Grimm, R.H., Cutler, J.A., Simons-Morton, D.G., Basile, J.N., and Corson, M.A. (2010). Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med., 362, 1575\u20131585.","DOI":"10.1056\/NEJMoa1001286"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"SPRINT Research Group, Wright, J.T., Williamson, J.D., Whelton, P.K., Snyder, J.K., Sink, K.M., Rocco, M.V., Reboussin, D.M., Rahman, M., and Oparil, S. (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N. Engl. J. Med., 373, 2103\u20132116.","DOI":"10.1056\/NEJMoa1511939"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"SPRINT Research Group, Lewis, C.E., Fine, L.J., Beddhu, S., Cheung, A.K., Cushman, W.C., Cutler, J.A., Evans, G.W., Johnson, K.C., and Kitzman, D.W. (2021). Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N. Engl. J. Med., 384, 1921\u20131930.","DOI":"10.1056\/NEJMoa1901281"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e008322","DOI":"10.1161\/CIRCHEARTFAILURE.121.008322","article-title":"Incidence and Outcomes of Acute Heart Failure with Preserved Versus Reduced Ejection Fraction in SPRINT","volume":"14","author":"Upadhya","year":"2021","journal-title":"Circ. Heart Fail."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/eurjpc\/zwad142","article-title":"Achieved systolic blood pressure and cardiovascular outcomes in 60\u201380-year-old patients: The Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial","volume":"30","author":"Deng","year":"2023","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/heartjnl-2018-314438","article-title":"Management of blood pressure in heart failure","volume":"105","author":"Rahimi","year":"2019","journal-title":"Heart"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s11886-022-01706-4","article-title":"How Much Lowering of Blood Pressure Is Required to Prevent Cardiovascular Disease in Patients with and without Previous Cardiovascular Disease?","volume":"24","author":"Canoy","year":"2022","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ahj.2010.12.009","article-title":"Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: A complex relationship","volume":"16","author":"Ather","year":"2011","journal-title":"Am. Heart J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/ejhf.1835","article-title":"Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients","volume":"22","author":"Cautela","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijcard.2020.05.084","article-title":"Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: A contemporary meta-analysis","volume":"316","author":"Gallo","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/eurheartj\/ehac759","article-title":"Endocrine functions of the heart: From bench to bedside","volume":"44","author":"Volpe","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1093\/eurheartj\/ehab489","article-title":"Sacubitril\/valsartan for heart failure with preserved ejection fraction and resistant hypertension: One shot for a double strike?","volume":"42","author":"Volpe","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_63","first-page":"1900","article-title":"Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials","volume":"293","author":"Kowalski","year":"2005","journal-title":"JAMA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesirtide in patients with acute d compensated heart failure","volume":"365","author":"Starling","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ahj.2013.08.001","article-title":"Learning from recent trials and shaping the future of acute heart failure trials","volume":"166","author":"Mentz","year":"2013","journal-title":"Am. Heart J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ejhf.2848","article-title":"Natriuretic peptides: Role in the diagnosis and management of heart failure: A scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society","volume":"25","author":"Tsutsui","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e004007","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials with 22,528 Patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study","volume":"139","author":"Kario","year":"2019","journal-title":"Circulation"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: A randomized, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","article-title":"Effects of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: A post hoc analysis","volume":"16","author":"Pfeifer","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1681\/ASN.2020050723","article-title":"Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial","volume":"31","author":"Oshima","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.122.059150","article-title":"Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition","volume":"146","author":"Lytvyn","year":"2022","journal-title":"Circulation"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e00303","DOI":"10.1002\/edm2.303","article-title":"Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"5","author":"Seidu","year":"2022","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/CIRCHEARTFAILURE.113.000481","article-title":"Low-Sodium DASH Diet Improves Diastolic Function and Ventricular\u2013Arterial Coupling in Hypertensive Heart Failure with Preserved Ejection Fraction","volume":"6","author":"Hummel","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1161\/HYPERTENSIONAHA.112.202705","article-title":"Low-Sodium Dietary Approaches to Stop Hypertension Diet Reduces Blood Pressure, Arterial Stiffness, and Oxidative Stress in Hypertensive Heart Failure with Preserved Ejection Fraction","volume":"60","author":"Hummel","year":"2012","journal-title":"Hypertension"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e004886","DOI":"10.1161\/CIRCHEARTFAILURE.117.004886","article-title":"Home-Delivered Meals Postdischarge from Heart Failure Hospitalization","volume":"11","author":"Hummel","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/08998280.2015.11929216","article-title":"Impact of the DASH diet on endothelial function, exercise capacity, and quality of life in patients with heart failure","volume":"28","author":"Rifai","year":"2015","journal-title":"Bayl. Univ. Med. Cent. Proc."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Wickman, B.E., Enkhmaa, B., Ridberg, R., Romero, E., Cadeiras, M., Meyers, F., and Steinberg, F. (2021). Dietary Management of Heart Failure: DASH Diet and Precision Nutrition Perspectives. Nutrients, 13.","DOI":"10.3390\/nu13124424"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone Reduces Risk of Incident Heart Failure in Patients with Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"ref_86","unstructured":"(2020, June 17). Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants with Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04435626."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/HYPERTENSIONAHA.120.16397","article-title":"Effect of Mineralocorticoid Receptor Blockade on Arterial Stiffness and Endothelial Function: A Meta-Analysis of Randomized Trials","volume":"77","author":"Sakima","year":"2021","journal-title":"Hypertension"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.phrs.2011.01.014","article-title":"Role of endothelin in the cardiovascular system","volume":"63","author":"Busnadiego","year":"2011","journal-title":"Pharmacol. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1161\/01.CIR.0000094397.19932.78","article-title":"Endothelin receptor blockers in cardiovascular disease","volume":"108","author":"Rich","year":"2003","journal-title":"Circulation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41569-019-0176-3","article-title":"Endothelins in Cardiovascular Biology and Therapeutics","volume":"16","author":"Dhaun","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/oxfordjournals.eurheartj.a015228","article-title":"Prognostic value of plasma endothelin-1 in patients with chronic heart failure","volume":"18","author":"Pousset","year":"1997","journal-title":"Eur. Heart J."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Boutari, C., and Siskos, F. (2023). Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension. Life, 13.","DOI":"10.3390\/life13030806"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0895-7061(02)02933-3","article-title":"Darusentan: An effective endothelinA receptor antagonist for treatment of hypertension","volume":"15","author":"Nakov","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/HYPERTENSIONAHA.110.156976","article-title":"Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial","volume":"56","author":"Bakris","year":"2010","journal-title":"Hypertension"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","article-title":"Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist","volume":"327","author":"Iglarz","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/jpet.116.234930","article-title":"Endothelin ETA Receptor Blockade, by Activating ETB Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retention","volume":"361","author":"Vercauteren","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/jch.14517","article-title":"Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan","volume":"24","author":"Danaietash","year":"2022","journal-title":"J. Clin. Hypertens."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/08037051.2016.1208730","article-title":"Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: A meta-analysis","volume":"26","author":"Yuan","year":"2017","journal-title":"Blood Press."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e003381","DOI":"10.1161\/CIRCHEARTFAILURE.116.003381","article-title":"Dual Endothelin-A\/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure with Preserved Ejection Fraction","volume":"9","author":"Li","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchf.2017.02.021","article-title":"Long-Term Effect of Endothelin Receptor Antagonism with Bosentan on the Morbidity and Mortality of Patients with Severe Chronic Heart Failure: Primary Results of the ENABLE Trials","volume":"5","author":"Packer","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.lfs.2012.07.034","article-title":"Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?","volume":"91","author":"Kohan","year":"2012","journal-title":"Life Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2174\/1871530318666180212095235","article-title":"Vasopressin in Heart Failure","volume":"18","author":"Iovino","year":"2018","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Wang, C., Xiong, B., and Cai, L. (2017). Effects of Tolvaptan in patients with acute heart failure: A systematic review and meta-analysis. BMC Cardiovasc. Disord., 17.","DOI":"10.1186\/s12872-017-0598-y"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"A14387","DOI":"10.1161\/circ.142.suppl_3.14387","article-title":"Abstract 14387: Dose-related reductions in blood pressure with a rna interference (rnai) therapeutic targeting angiotensinogen in hypertensive patients: Interim results from a first-in-human phase 1 study of aln-agt01","volume":"142","author":"Huang","year":"2020","journal-title":"Circulation"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e027694","DOI":"10.1161\/JAHA.122.027694","article-title":"Small Interfering RNA Therapeutics in Hypertension: A Viewpoint on Vasopressor and Vasopressor-Sparing Strategies for Counteracting Blood Pressure Lowering by Angiotensinogen-Targeting Small Interfering RNA","volume":"11","author":"Ranasinghe","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA Interference with Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"key":"ref_110","unstructured":"(2021, November 02). Zilebesiran as Add-on Therapy in Patients with Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05103332."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/12\/6661\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:00:14Z","timestamp":1760108414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/12\/6661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":111,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ijms25126661"],"URL":"https:\/\/doi.org\/10.3390\/ijms25126661","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]}}}